3B Blackbio Dx Limited share price
3B Blackbio Dx Limited manufactures and sells molecular diagnostic kits in India. The company designs, develops, manufactures and commercializes qPCR assays, rapid diagnostic tests, NGS-based diagnostic kits, digital PCR assays, and nucleic acid extraction solutions for reliable testing of patient samples, as well as offers oncology and hematology, antimicrobial resistance, infectious diseases, human genetics, extraction, and rapid antigen kits under the TRUPCR, TRUNGS, and TRURAPID brand names; and technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.Read more
- Market Cap₹ 1,241 Cr.
- Current Price₹ 1,446.40
- High / Low₹ 1,740 / 1,100
- Stock P/E21.8
- Book Value₹ 388
- Dividend Yield0.35 %
- ROCE22.6 %
- ROE20.20 %
- Face Value—
More figures (10)
- EPS (TTM)₹ 66.27
- Price / Book3.72
- OPM38.9 %
- Debt / Equity0.01
- Sales growth (4Y)31.9 %
- Profit growth (4Y)32.2 %
- Promoter holding63.9 %
- EV / EBITDA22.2
- Beta0.38
- All-time high₹ 1,740
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| 3BBLACKBIO | +11.90% | — | — | — | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- 3B Blackbio Dx Limited is in the Biotechnology industry (Healthcare), with a market value of ₹1,241 crore.
- It trades at 21.8 times its last 12 months' earnings and 3.7 times book value.
- Revenue grew 31.9% a year over the last 4 years, profit 32.2% a year.
- Return on equity was 20.2% and return on capital employed 22.6% in the latest year.
- Debt was 0.01 times shareholders' equity.
- The share price is 16.9% below its 52-week high.
- Promoters and insiders hold about 63.9%; institutions about 2.0%.
Pros
AI- Strong return on equity: 18.4% on average over the last 3 years.
- Company is almost debt-free (debt is 0.01 times equity).
Cons
AINo standout weaknesses in the reported figures.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About 3B Blackbio Dx Limited
3B Blackbio Dx Limited manufactures and sells molecular diagnostic kits in India. The company designs, develops, manufactures and commercializes qPCR assays, rapid diagnostic tests, NGS-based diagnostic kits, digital PCR assays, and nucleic acid extraction solutions for reliable testing of patient samples, as well as offers oncology and hematology, antimicrobial resistance, infectious diseases, human genetics, extraction, and rapid antigen kits under the TRUPCR, TRUNGS, and TRURAPID brand names; and technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.
- Employees
- 86
- Head office
- Bhopal
Peer comparison
HealthcareBiotechnology
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | 3B Blackbio Dx | 1,446.40 | 21.8 | 1,241 | 0.35 | 10 | -24.29 | 33 | 50.62 | 22.6 | 20.2 | 3.72 | 38.9 | 0.01 | 63.94 | 142 | 31.9 |
| 2. | Biocon | 349.20 | 103.3 | 57,190 | 0.14 | 137 | 53.36 | 4,336 | 10.00 | 2.8 | 1.4 | 1.66 | 10.3 | 0.45 | 48.12 | 16,927 | 15.3 |
| 3. | Anthem Biosciences | 822.15 | 81.0 | 46,330 | 0.24 | 120 | -11.67 | 418 | -22.58 | 26.8 | 21.7 | 15.18 | 33.2 | 0.02 | 80.89 | 2,124 | 26.2 |
| 4. | OneSource Specialty Pharma | 1,407.80 | — | 16,144 | 0.00 | 25 | — | 449 | 37.20 | 0.3 | -1.3 | 2.77 | -0.4 | 0.26 | 35.49 | 1,422 | 232.4 |
| 5. | Concord Biotech | 1,339.00 | 46.1 | 14,008 | 0.56 | 58 | 30.96 | 257 | 26.23 | 16.7 | 13.6 | 6.94 | 29.1 | 0.00 | 72.48 | 1,055 | 8.0 |
| 6. | Blue Jet Healthcare | 520.65 | 38.4 | 9,031 | 0.23 | 78 | -28.91 | 293 | -13.90 | 24.0 | 19.9 | 6.64 | 28.6 | 0.03 | 76.02 | 944 | 9.4 |
| 7. | Supriya Lifescience | 886.00 | 35.9 | 7,131 | 0.11 | 24 | -30.89 | 190 | 30.79 | 22.3 | 19.1 | 5.96 | 31.7 | 0.00 | 71.28 | 828 | 21.2 |
| 8. | Dishman Carbogen Amcis | 149.83 | 146.9 | 2,349 | 0.00 | -58 | -347.24 | 678 | -4.29 | 2.7 | 1.6 | 0.35 | 6.9 | 0.46 | 69.30 | 2,932 | 7.5 |
| 9. | Lyka Labs | 87.79 | — | 317 | 0.00 | 2 | 105.44 | 42 | 28.11 | -7.1 | -10.2 | 3.39 | -9.4 | 0.53 | 60.39 | 128 | 13.3 |
| Median: 9 Co. | 822.15 | 46.1 | 9,031 | 0.14 | 25 | -17.98 | 293 | 26.23 | 16.7 | 13.6 | 3.72 | 28.6 | 0.03 | 69.30 | 1,055 | 15.3 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 22 | 34 | 50 | 35 | 33 |
| Operating Profit | 12 | 14 | 21 | 5 | 7 |
| Profit before tax | 16 | 20 | 27 | 15 | 13 |
| Net Profit | 13 | 15 | 22 | 10 | 10 |
| EPS in Rs | 14.67 | 17.55 | 25.32 | 11.44 | 11.11 |
Profit & Loss
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 62 | 74 | 96 | 142 | |
| Operating Profit | 29 | 32 | 49 | 55 | |
| Interest | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 5 | |
| Profit before tax | 35 | 44 | 64 | 77 | |
| Net Profit | 26 | 33 | 48 | 60 | |
| EPS in Rs | 30.27 | 37.46 | 55.66 | 69.94 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 |
| Reserves | 185 | 214 | 260 | 316 |
| 2 | 1 | 0 | 5 | |
| Long term borrowings | 1 | 1 | 0 | 3 |
| Short term borrowings | 1 | |||
| 19 | 24 | 27 | 49 | |
| Trade payables | 3 | 4 | 2 | 7 |
| Minority interest | 3 | 2 | 3 | 7 |
| Current liabilities | 14 | 18 | 19 | 37 |
| Total Liabilities | 214 | 248 | 296 | 378 |
| 8 | 7 | 19 | 22 | |
| Gross block | 14 | 14 | 47 | 53 |
| Accumulated depreciation | 6 | 7 | 28 | 31 |
| Goodwill & intangibles | 1 | 6 | ||
| CWIP | 0 | |||
| 206 | 241 | 277 | 356 | |
| Inventories | 8 | 8 | 9 | 18 |
| Trade receivables | 34 | 36 | 37 | 50 |
| Cash & equivalents | 5 | 13 | 12 | 38 |
| Current assets | 114 | 123 | 132 | 193 |
| Total Assets | 214 | 248 | 296 | 378 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 20 | 27 | 43 | 52 | |
| Profit for the year | 26 | 33 | 48 | 60 |
| Working capital changes | -5 | -2 | -1 | -11 |
| Direct taxes paid | -9 | -11 | -15 | -16 |
| 15 | -20 | -34 | -24 | |
| Fixed assets purchased | -2 | -1 | -1 | -26 |
| Investments purchased | -20 | -33 | -6 | |
| Investments sold | 14 | |||
| -5 | -4 | -3 | -1 | |
| Proceeds from borrowings | 0 | |||
| Repayment of borrowings | -1 | -1 | -1 | |
| Interest paid | -0 | -0 | -0 | -0 |
| Dividends paid | -4 | -2 | -3 | -3 |
| Net Cash Flow | 30 | 3 | 6 | 28 |
| Free Cash Flow | 18 | 26 | 42 | 27 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 13.4% | 15.7% | 19.4% | 20.2% |
| ROCE | — | 17.8% | 19.3% | 23.1% | 22.6% |
| Operating margin | — | 46.3% | 43.1% | 51.1% | 38.9% |
| Net margin | — | 41.9% | 44.2% | 49.4% | 42.2% |
| Debt / equity | — | 0.01 | 0.00 | 0.00 | 0.01 |
| Current ratio | — | 8.05 | 7.04 | 7.11 | 5.27 |
| Debtor days | — | 200 | 178 | 138 | 129 |
| Inventory days | — | 164 | 141 | 124 | 187 |
| Days payable | — | 69 | 66 | 28 | 70 |
| Cash conversion cycle | — | 295 | 253 | 234 | 246 |
| Working capital days | — | 591 | 521 | 430 | 402 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 63.94%
- Institutions (FII, DII, funds) 1.95%
- Public & others 34.11%
Key dates
- Ex-dividend date
- 22 Sep 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
From the company (NSE)
No recent announcements.
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about 3B Blackbio Dx Limited
What is the share price of 3B Blackbio Dx Limited today?
What is the market cap of 3B Blackbio Dx Limited?
What is the P/E ratio of 3B Blackbio Dx Limited?
Is 3B Blackbio Dx Limited a good investment?
How can I buy 3B Blackbio Dx Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.